Compare TECX & DCTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TECX | DCTH |
|---|---|---|
| Founded | 2019 | 1988 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Medical/Dental Instruments |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 359.0M | 289.2M |
| IPO Year | 2018 | N/A |
| Metric | TECX | DCTH |
|---|---|---|
| Price | $20.98 | $10.02 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 5 |
| Target Price | ★ $81.20 | $22.60 |
| AVG Volume (30 Days) | 407.9K | ★ 816.4K |
| Earning Date | 11-06-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.03 |
| Revenue | N/A | ★ $79,603,000.00 |
| Revenue This Year | N/A | $131.97 |
| Revenue Next Year | N/A | $38.84 |
| P/E Ratio | ★ N/A | $292.41 |
| Revenue Growth | N/A | ★ 251.54 |
| 52 Week Low | $13.70 | $8.12 |
| 52 Week High | $61.07 | $18.23 |
| Indicator | TECX | DCTH |
|---|---|---|
| Relative Strength Index (RSI) | 59.16 | 58.95 |
| Support Level | $18.60 | $9.25 |
| Resistance Level | $22.00 | $9.80 |
| Average True Range (ATR) | 1.72 | 0.48 |
| MACD | 0.09 | 0.20 |
| Stochastic Oscillator | 78.88 | 95.00 |
Tectonic Therapeutic Inc is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Its technology platform called GEODe, Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery to modify the course of disease. Company focus on areas of important unmet medical need, often where therapeutic options are poor or nonexistent, and where new medicines have the potential to improve patient quality of life or extend duration of life. Pipeline includes TX000045, Group 2 PH, TX2100: GPCR Antagonist for Hereditary Hemorrhagic Telangiectasia (HHT), Fibrosis.
Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.